The National Cancer Institute and Division of Cancer Biology announce the formation of the Chemical Carcinogen Reference Standards Synthesis Program, which can provide difficult-to-obtain chemicals for NIH- and NCI-supported researchers. This program replaces the Chemical Carcinogen Reference Standards Repository that was available through the Midwest Research Institute.
Eligibility: Requests will only be accepted from investigators with current NIH funding. Requested chemicals must be related to research described in the Specific Aims of an NIH grant with current active funding. Requests will not be accepted from investigators funded from other non-NIH sources, or from foreign grantees.
Application Format and Submission: Requests for chemicals may be submitted at any time and should be submitted electronically in MS Word or PDF format. Requests should be no more than two pages in length, including references. The application should contain the following information:
- The chemical to be synthesized (from the list of 70 compounds on the table below) and the quantity required. Requested quantities should be limited to that which is appropriate for the work proposed in the funding period of the associated grant.
- A description of how the chemical is to be used, and how this use is related to an existing NIH grant. Grants should be identified by Grant Number.
- A justification of why the chemical is needed, and why it cannot be obtained from other sources.
Requests must be countersigned by the requestor's Grants Administrative Official. They should be sent via email to Program Officer Ellen Zaika at zaikae@mail.nih.gov
Review: Requests for chemicals will be reviewed by NCI/DCB Program staff as they are received. Priority will be given in the following order: 1) DCB-funded grantees, 2) NCI-funded grantees, and 3) other NIH IC-funded grantees. Requests will be ranked on the basis of the need of the requested chemical for completion of the Aims of the funded grant, significance of the research utilizing the chemical, and programmatic considerations of the Cancer Etiology Branch, the DCB, and the NCI. Requests will be filled in rank order, based on the availability of funds.
Requestors will be notified by NCI or the contractor when synthesis of the requested chemical is initiated, with an estimate of when the chemical will be shipped. Requests will remain active for three additional review cycles. If requests are not selected for synthesis within that time, they will be discarded and the requestor will need to submit a new application.
Reports: Recipients of the compounds from the DCB Repository are required to acknowledge the support of the Repository whenever publicizing the work resulting from these NCI-supplied compounds in any media by including an acknowledgement statement essentially as follows: "This project was performed in part using compound(s) provided by the NCI operated under contract by The Pennsylvania State University, College of Medicine HHSSN261200900026C."
Within 1 year, applicants receiving compounds should submit a report electronically (to zaikae@mail.nih.gov) indicating how compounds were used and the scientific results obtained. Links to publications resulting from the use of the chemicals provided should be included in the report. Failure to provide a report may result in future requests being denied.
List of Chemicals available from the Chemical Carcinogen Reference Standards Synthesis Program
|
Chemical |
PSU # |
NCI# |
| 1 |
Benzo[a]pyrene |
101 |
G0074 |
| 2 |
1-Hydroxybenzo[a]pyrene |
102 |
L0100 |
| 3 |
3-Hydroxybenzo[a]pyrene |
103 |
L0075 |
| 4 |
7-Hydroxybenzo[a]pyrene |
104 |
L0105 |
| 5 |
9-Hydroxybenzo[a]pyrene |
105 |
L0106 |
| 6 |
Benzo(a)pyrene-trans-7,8-dihydrodiol(+/-) |
106 |
L0113 |
| 7 |
Benzo(a)pyrene-trans-9,10-dihydrodiol |
107 |
L0114 |
| 8 |
Benzo(a)pyrene-trans-7,8-dihydrodiol (-) |
108 |
O0468 |
| 9 |
Benzo(a)pyrene-trans-7,8-dihydrodiol (+) |
109 |
O0473 |
| 10 |
Benzo(a)pyrene-r-7,t-8,t-9,t-10-tetrahydrotetrol(+/-) |
110 |
L0618 |
| 11 |
Benzo(a)pyrene-r-7,t-8,t-9,c-10-tetrahydrotetrol(+/-) |
111 |
L0619 |
| 12 |
Benzo(a)pyrene-r-7,t-8,c-9,t-10-tetrahydrotetrol(+/-) |
112 |
L0629 |
| 13 |
Benzo(a)pyrene-4,5-dihydroepoxide(+/-) |
113 |
L0115 |
| 14 |
Benzo(a)pyrene-r-7,t-8-dihydrodiol-t-9,10-epoxide(+/-) (anti) |
114 |
L0137 |
| 15 |
Benzo(a)pyrene-r-7,t-8-dihydrodiol-c-9,10-epoxide(+/-) (syn) |
115 |
L0152 |
| 16 |
Benzo(a)pyrene-1,6-dione |
116 |
L0109 |
| 17 |
Benzo(a)pyrene-3,6-dione |
117 |
L0110 |
| 18 |
Benzo(a)pyrene-6,12-dione |
118 |
L0111 |
| 19 |
Benzo(a)pyrene-7,8-dione |
119 |
L0288 |
| 20 |
Benzo(a)pyrene-r-7,t-8,c-9,c-10-tetrahydrotetrol(+/-) |
120 |
L0621 |
| 21 |
Benzo(a)pyrene-trans-7,8-dihydrodiol-9,10-epoxide (anti) (+) |
121 |
P0702 |
| 22 |
Benzo(a)pyrene-7,8-dihydroepoxide(+/-) |
122 |
L0622 |
| 23 |
Benzo(a)pyrene-trans-4,5-dihydrodiol(+/-) |
123 |
L0129 |
| 24 |
3-Benzo(a)pyrenyl-B-D-glucopyranosiduronic acid |
124 |
K0343 |
| 25 |
7R,8S,9S-Trihydroxy-10S-(N2-deoxyguanosyl-3'-phosphate)-7,8,9,10-tetrahydrobenzo[a]pyrene |
125 |
AD0884 |
|
| 26 |
1-Hydroxybenz(a)anthracene |
126 |
L0191 |
| 27 |
3-Hydroxybenz(a)anthracene |
127 |
L0193 |
| 28 |
Benz(a)anthracene-trans-3,4-dihydrodiol |
128 |
L0187 |
| 29 |
Benz(a)anthracene-trans-3,4-dihydrodiol-1,2-epoxide (anti) |
129 |
L0189 |
| 30 |
Benz(a)anthracene-trans-8,9-dihydrodiol-10,11-epoxide (syn) |
130 |
L0155 |
| 31 |
Benz[a]anthracene-trans-8,9-dihydrodiol-10,11-epoxide (anti) |
131 |
L0154 |
| 32 |
7,12-Dimethylbenz(a)anthracene-trans-3,4-dihydrodiol |
132 |
L0751 |
| 33 |
Dibenzo[a,l]pyrene |
133 |
G0479 |
| 34 |
(+/-)-r-11,t-12-Dihydroxy-t-13,14-epoxy-11,12,13,14-tetrahydrodibenzo[a,l]pyrene (anti) |
134 |
L0980 |
| 35 |
Chrysene-trans-1,2-dihydrodiol-3,4-epoxide (anti) |
135 |
L0500 |
| 36 |
Chrysene-trans-1,2-dihydrodiol-3,4-epoxide (syn) |
136 |
L0512 |
| 37 |
3-Hydroxychrysene |
137 |
L0413 |
| 38 |
1-Hydroxychrysene |
138 |
L0460 |
| 39 |
Benzo[c]phenanthrene-3,4-diol-1,2-epoxide |
139 |
L0983 |
| 40 |
1-Hydroxybenzo[c]phenanthrene |
140 |
L1106 |
| 41 |
Benzo[g]chrysene-11,12-diol-13,14-epoxide (anti) |
141 |
M1013 |
| 42 |
1-Pyrenyl-B-D-Glucopyranosiduronic acid |
142 |
K1103 |
| 43 |
1-Hydroxypyrene |
143 |
L0723 |
| 44 |
Dibenz(a,c)anthracene-trans-10,11-dihydrodiol-12,13-epoxide (anti) |
144 |
L0456 |
| 45 |
(+/-)-anti-7,12-Dimethylbenz[a]anthracene-3,4-dihydrodiol-1,2-epoxide |
145 |
L1313 |
|
| 46 |
(+/-)-syn-7,12-Dimethylbenz[a]anthracene-3,4-dihydrodiol-1,2-epoxide |
146 |
L1312 |
|
| 47 |
1,2-Dihydroxy-3,4-epoxy-1,2,3,4-tetrahydrophenanthrene (anti) |
147 |
L1317 |
|
| 48 |
5-Methylchrysene |
148 |
M0866 |
| 49 |
5-Methylchrysene-r-1,t-2,3,c-4-tetrahydrotetrol |
149 |
L0870 |
| 50 |
Cyclopenta[c,d]pyrene |
150 |
J0471 |
| 51 |
Dibenzo[a,i]pyrene (Benzo[rst]pentaphene) |
151 |
G0062 |
| 52 |
Benzo(k)fluoranthene-trans-8,9-dihydrodiol-10,11-epoxide (anti) |
152 |
L0746 |
|
| 53 |
Benzo(b)fluoranthene-trans-9,10-dihydrodiol-11,12-epoxide (anti) |
153 |
L0798 |
|
| 54 |
N-Nitrosomethylurea (NMU) |
201 |
E0049 |
| 55 |
N-Methylacetoxymethylnitrosamine |
202 |
E0215 |
| 56 |
N-Nitroso-L-proline |
203 |
E0174 |
| 57 |
N-Nitrosonornicotine (NNN) |
204 |
E0151 |
| 58 |
N-Methylbenzylnitrosamine |
205 |
E0089 |
| 59 |
4-(N-Methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK) |
206 |
E0698 |
| 60 |
N-Nitrosoanabasine |
207 |
E0840 |
| 61 |
N-Nitrosoanatabine |
208 |
E0831 |
| 62 |
4-(N-Methyl-nitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) |
209 |
E1154 |
| 63 |
N-Nitrosoguvacoline |
210 |
E1061 |
| 64 |
N-Acetoxy-2-acetylaminofluorene |
301 |
AM0030 |
| 65 |
Azoxymethane |
302 |
F0044 |
| 66 |
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) |
303 |
D0440 |
| 67 |
Methylazoxy methanol acetate |
304 |
F0040 |
| 68 |
7H-Dibenzo(c,g)carbazole |
305 |
H0258 |
| 69 |
2-Hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine (N-Hydroxy PhIP) |
306 |
L1096 |
|
| 70 |
Cholanthrene |
307 |
G0502 |
| |